Recovered patients and used for plasma transfusion swice in a volume of 200 to 250ml on the day of collection (310. At present, treatment for sepsis and ARDS mainly involves antimicrobial therapy, source control, and supportive care. Hence, the use of therapeutic plasma exchange can be considered an option in managing such severe conditions. Further randomized trials can be designed to investigate its efficacy(311).  
Potential Therapeutic Agents  
Potent therapeutics to combat SARS-CoV-2 infection include virus binding molecules, molecules or inhibitors targeting particular enzymes implicated in replication and transcription process of the virus, helicase inhibitors of host cells, endocytosis inhibitors, short interfering RNA(siRNA), neutralizing antibodies, Mabs against the host receptor, Mabs interfering with the S1 RBD, antiviral peptide aimed at S2, and natural drugs/medicines (7,166,186). The S protein acts as the critical target for developing CoV antivirals, like inhibitors of S protein and S cleavage, neutralizing antibodies, RBD-ACE2 blockers, siRNAs, blockers of the fusion core, and proteases (168).  
All of these therapeutic approaches have revealed